Product information and disease descriptionPlace of product in therapyDisease description
Diagnosis
16 evidence topics · 16 sources
Whipple triad: diagnostic hallmark of a hypoglycemic disorder
“The Whipple triad, named after the American surgeon Allen O. Whipple (1881-1963), is the diagnostic hallmark establishing the existence of a hypoglycemic disorder and has the following 3 features: (1) symptoms, signs, or both consistent with hypoglycemia; (2) low plasma glucose measured at the time of the symptoms and signs; and (3) relief of symptoms and signs when the glucose is raised to a normal level” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endocrine Society guideline: evaluation of adults with hypoglycemia
“We recommend evaluation and management of hypoglycemia only in patients in whom Whipple's triad” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In patients suspected of having endogenous hyperinsulinism, measure plasma glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and circulating oral hypoglycemic agents during an episode of hypoglycemia and measure insulin antibodies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: biochemical diagnostic criteria
“Thus, in patients with insulinoma, plasma insulin, C-peptide, and proinsulin concentrations are inappropriately high in the setting of low fasting plasma glucose concentrations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“According to the most recent clinical practice guidelines, critical diagnostic findings are present when the confirmed fasting plasma glucose concentrations are preferably below 45 mg/dL (2.5 mmol/L) or below 55 mg/dL (3.0 mmol/L)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: corrected insulin, C-peptide, and proinsulin thresholds
“plasma insulin concentrations of at least 3 μU/mL (18 pmol/L), plasma C-peptide concentrations of at least 0.6 ng/mL (0.2 nmol/L), and plasma proinsulin concentrations of at least 5.0 pmol/L” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The sensitivity and specificity of the established diagnostic criteria using insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and glucose response to iv glucagon were greater than 90% and greater than 70%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: supervised prolonged fasting test
“If hypoglycemia does not occur spontaneously, a 72-hour prolonged fasting test should be performed and blood should be drawn for measurements of insulin, and pro-insulin, or C-peptide measurements if hypoglycemia occurs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Some authors have advocated shorter fasting tests” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We identified 127 patients with insulinoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The fast was terminated due to hypoglycemia in 44 patients (42.5%) by 12 h, 85 patients (66.9%) by 24 h, and 120 (94.5%) by 48 h.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, the 48-h fast should replace the 72-h fast in textbooks and hospital protocols as the new diagnostic standard.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sixty-five patients underwent a fasting test, aiming at a 24, 36, or 72-hour fasting time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“were met in 92% of the tests, after a median fasting time of 14 (0, 36) hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: beta-hydroxybutyrate stopping criterion in the 72-hour fast
“After the update, 50% (N = 15) ended for BHB >2.7 mmol/L, with an average fast duration of 49.7 hours (median 53 hours, IQR [39.1, 71.8], P = .03).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All insulinoma cases (N = 7) developed hypoglycemia within 43 hours with BHB ≤1.2 mmol/L; no cases were missed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: localization imaging strategy
“Localization of the insulinoma and exclusion or confirmation of metastatic disease by CT is still the preferred initial localization modality followed by EUS or magnetic resonance imaging (MRI) for indolent, localized insulinomas” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Glucagon-like peptide 1 receptor (GLP-1R) PET/CT or PET/MRI is a highly sensitive localization technique for seemingly occult, indolent, localized insulinomas and has become increasingly popular.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Preoperative localization of nonmetastatic insulinomas is important and sometimes difficult, because approximately 30% of insulinomas are less than 10 mm in diameter.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, as opposed to localized indolent insulinomas, aggressive malignant insulinomas often lack the expression of the GLP-1R.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: sensitivity and specificity of localization modalities across published studies
Insulinoma: GLP-1 receptor PET/CT in a prospective multicenter comparison
“Sixty-nine adults with biochemically proven adult endogenous hyperinsulinemic hypoglycemia underwent exendin PET/CT and current routine imaging.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on clinical readings, the accuracy of exendin PET/CT (94.4%; 95% CI, 84.6%–98.8%) was greater than that of DOTA-SSA PET/CT (64.8%; 95% CI, 50.6%–77.3%), contrast-enhanced CT/contrast-enhanced diffusion-weighted imaging-MRI (83.3%; 95% CI, 70.7%–92.1%), and endoscopic ultrasound (82.8%; 95% CI, 64.1%–94.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 13% of patients, a correct diagnosis was only reached after exendin PET/CT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: GLP-1 receptor SPECT/CT in a prospective multicenter study
“For 23 assessable patients, (111)In-DTPA-exendin-4 SPECT/CT had a higher sensitivity (95% [95% CI 74-100]) than did CT/MRI (47% [27-68]; p=0.011).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Seven patients (23%) were referred to surgery on the basis of (111)In-DTPA-exendin-4 imaging alone.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: preoperative localization over time in cohort studies
“The overall imaging sensitivity improved from 39% in the 1980s to 98% in the 2000s” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The tumour was localized preoperatively in 59 (75%) of the patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the rates of localization by noninvasive techniques remained static at approximately 75%, the addition of invasive modalities has resulted in successful preoperative localization in all patients in the past 10 yr.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Insulinoma: diagnostic delay and prior misdiagnosis
“The median diagnostic delay was 13 months and did not change over the study period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-one of 79 patients were first examined for their symptoms by specialities other than endocrinology, most often by neurology, neurosurgery, or cardiology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The episodic symptoms were often interpreted as cerebrovascular disorders, epilepsy, or psychiatric disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The interval from the onset of symptoms to diagnosis ranged from 1 month to 30 years (median 24 months).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Prior diagnoses included neurologic disorders (64%), especially seizure disorders (39%); 7 (12%) patients were treated with antiseizure medications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Malignant insulinoma: biochemical and tumor-size features at diagnosis
“Patients with malignant insulinoma presented with higher levels of insulin, proinsulin, and c-peptide.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Malignant lesions were larger: 4.2 ± 3.2 vs 1.8 ± 0.8 cm in benign lesions, p < 0.01.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NICTH: biochemical pattern and IGF-2 to IGF-1 ratio
“In a hypoglycemic patient with low insulin and C-peptide, a low β-hydroxybutyrate level suggests an agent mimicking insulin and is therefore an indication to measure IGF-I and IGF-II” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The typical pattern for NICTH on the above laboratory studies includes low glucose (serum glucose < 55 mg/dL) with simultaneous low insulin/proinsulin/C-peptide/β-hydroxybutyrate levels, and the absence of positive results on an oral hypoglycemic agent screen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This ratio may be an important screening tool for NICTH in cases of hypoglycemia” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Typically, the elevated IGF-2 levels are associated with suppressed plasma levels of insulin, IGF-1, and GH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A ratio of IGF‐2 and IGF‐1 in a healthy individual is 3:1. A molar ratio larger than 10 in recurrent hypoglycaemia supports NICTH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“an 88% positivity rate for IGF2:IGF1 ratio>10” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICTH: hypoinsulinemia and tumor size in a Japanese case series
“Basal immunoreactive insulin (IRI) levels were less than 3 microU/dl in 79% of the patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The diameters of the tumors were more than 10 cm in 70% of the patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These data suggested that hypoinsulinemic hypoglycemia associated with the presence of a large tumor supports the diagnosis of IGF-II producing NICTH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NICTH: test availability and tumor imaging
“To our knowledge, there is no commercially available assay for big IGF-II, and measurement of high molecular weight precursor forms of IGF-II must be done in a research laboratory setting at this time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If laboratory results suggest NICTH (eg, high IGF-II:IGF-I ratio and absence of evidence for hyperinsulinemia), a reasonable next step is cross-sectional imaging of the chest, abdomen, and pelvis to identify a tumor, given that the vast majority of reported cases of NICTH involve a tumor in one of these sites.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the relative infrequency of testing for IGF‐1, IGF‐2 and pro‐IGF‐2 testing, the diagnosis of NICTH poses considerable challenges and is often overlooked, which may lead to significant clinical consequences.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote